Edwards sapien 3 tavr delivers proven long-term benefits and valve performance, new data presented at tct 2025

San francisco--(business wire)--edwards lifesciences (nyse: ew) today announced seven-year data from the partner 3 trial, reaffirming the early and sustained patient benefits of edwards tavr. the data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. separately, 10-year results from partner 2 intermediate risk studies reinforce edwards' leadership in setting the standard for lasting valve performance and excellent patien.
EW Ratings Summary
EW Quant Ranking